An automatic bio-decontamination system for everyone, everywhere

MICROBIAL CONTAMINATION

HEALTHCARE-ASSOCIATED INFECTIONS

7 x more in Portugal 2.5 x more in USA

KILL MORE PEOPLE THAN CAR CRASHES

ADDITIONAL HEALTHCARE COST

$25–$45 Bper year

Source: https://www.meticulousresearch.com/product/sterilization-equipment-market/

2

MICROBIAL CONTAMINATION

BIODEFENSE

Natural disease outbreaks (e.g., Ebola,

SARS, Zika)

Accidental biological threats

Bioterrorism

3

MICROBIAL CONTAMINATION

SPACE

Planetary protection

Medical device sterilization in space

Pharmacological applications (e.g. space-

rider bio-decontamination module)

4

THE ADDRESSED

PROBLEMLack of compact, portable, ultra-light weight and

electronic-friendly devices for automatic bio-

decontamination procedures.

5

Small chambers (up to 10 m3)

Compact device that releases and disperses hydrogen

peroxide vapor

DELOX SYSTEMFOR SMALL CHAMBERS

6

Safe and environmentally friendly sterilant

7

TECHNOLOGYNEW GENERATION OF

BIO-DECONTAMINATION DEVICES

Innovative solid formulation of the sterilant hydrogen peroxide

- patent pending (U.S. Application Number 62/807,393)

Faster aeration module (patent to be submitted)

Compact and simple device - patent pending (U.S. Application

Number 62/781,849)

GO-TO-MARKET STRATEGY

8

COMPOUNDING PHARMACIES IN

THE USABIODEFENSE SPACE

GO-TO-MARKET STRATEGY

9

COMPOUNDING PHARMACIES IN

THE USABIODEFENSE SPACE

SERVICEABLE ADDRESSABLE

MARKET SIZE

€400 M

Techsource Engineering (Erie, USA)

FIELD TESTS

GO-TO-MARKET STRATEGY

10

COMPOUNDING PHARMACIES IN

THE USABIODEFENSE SPACE

Portuguese Army: Laboratory of Bromatology and Biological Defense (Lisbon, Portugal)

PARTNER

GO-TO-MARKET STRATEGY

11

COMPOUNDING PHARMACIES IN THE USA

BIODEFENSE SPACE

“Delox is a good example of a highly innovative SME looking beyond standard markets. They go where no one else has gone before and this is the same curiosity which drives us.”

3U CubeSatDevelopment instrument

Frank M. Salzgeber

ESA Business Applications and ESA

Space Solutions

COMPETITION

Short cycle

lengthAffordability Efficacy Compactness

Electronics

compatibility

UVC cleaning

Tru-d

Devea

Oxypharm

Steris

Bioquell

Delox

Hy

dro

ge

n

Pe

rox

ide

UV

irr

ad

iati

on

12

ROADMAPTarget round

€ 2.4 M

13

December 2019 January 2021

June 2018 – company

incorporation

FIELD TESTS

ANNUAL PRODUCTION CAPACITY

PRODUCT DEVELOPMENT

10 kg

Techsource Engineering (Erie, USA)

Call to Orbit technology validation for Space 4.0

Continuous product development

Pre-Industrialization 2.000 kg

Regulatory body approval

Laboratory of Bromatology and Biological Defense (Lisbon, Portugal)

Market entry

(compounding

pharmacies)

Industrial ization

Payload launch

January 2020

TEAM

FADHIL MUSA

Founder/CEO

RAQUEL NOGUEIRA

Researcher

JOÃO PIRES DA SILVA,

PhD

Founder/CSO

FERNANDO ANTUNES,

PhD

Founder/CTO

KATARZYNA CHUDZIK

Project Manager

NON-EXECUTIVE

CHAIRMAN

Under hiring

14

AWARDS AND GRANTS

15

2017

B E S T F I N A L P I T C H

N O V O M U N D O P R I Z E

1 ST P L A C E A T

S C I E N CE I N 2B US IN E S S

P R O G R A M

2 ND P L A C E A T S P A C E

E X P L O R A T IO N M A S T E R S

2018

G R A N T EE A N D I N C UB A T EE

2 n d C O M PA N Y T O B E

A C C E P T E D I N T H E C A L L

T O O R B I T P R O J E CT

2019

S M E I N S T R UM E N T S

P H A S E I G R A N T E E

H E A D S T A RT G R A N T EE

P O R T UG A L 2 0 2 0

P R O G R A M G R A N T E E

3 R D P L A C E A T T H E F I N A L P I T C H C O M P E T IT IO N

An automatic bio-decontamination system for everyone,

everywhere